Cynthia Nicholson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cynthia Nicholson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Sheilagh Maguiness
Department of Dermatology University of Minnesota Minneapolis Minnesota USA
4 shared publications Christina Boull
Department of Dermatology, Division of Pediatric Dermatology University of Minnesota Minneapolis Minnesota USA
3 shared publicationsSiobhan Flanagan
Department of Diagnostic and Interventional Radiology University of Minnesota Minneapolis Minnesota USA
2 shared publications- Amy Song
University of Minnesota Medical School Minneapolis MN USA
1 shared publication Brenda Weigel
Department of Pediatric Hematology/Oncology University of Minnesota Minneapolis Minnesota USA
1 shared publication- Cameron Meyer-Mueller
Department of Dermatology Division of Pediatric Dermatology University of Minnesota Minneapolis Minnesota USA
1 shared publication
Latest Publications
- Open Access
- 6 October 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (2) , 292-295
Arteriovenous malformations as a presenting sign of PTEN hamartoma tumor syndrome: A case series
High‐flow vascular malformations have been associated with multiple syndromes including capillary malformation–arteriovenous malformation (CM–AVM) syndrome, hereditary hemorrhagic telangiectasia syndrome, and less commonly, phosphatase and tensin homolog hamartoma tumor syndrome (PHTS). We present a series of three patients with clinically challenging complex AVMs who were found to have underlying PHTS. In all patients, diagnosis was delayed, and the presence of the AVM prompted sampling and genetic testing for PHTS in the absence of other clinical features of the condition. This series highlights the importance of screening for PHTS in the setting of high‐flow vascular malformations.
- 6 October 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (2) , 292-295
Open AccessArteriovenous malformations as a presenting sign of PTEN hamartoma tumor syndrome: A case series
High‐flow vascular malformations have been associated with multiple syndromes including capillary malformation–arteriovenous malformation (CM–AVM) syndrome, hereditary hemorrhagic telangiectasia syndrome, and less commonly, phosphatase and tensin homolog hamartoma tumor syndrome (PHTS). We present a series of three patients with clinically challenging complex AVMs who were found to have underlying PHTS. In all patients, diagnosis was delayed, and the presence of the AVM prompted sampling and genetic testing for PHTS in the absence of other clinical features of the condition. This series highlights the importance of screening for PHTS in the setting of high‐flow vascular malformations.
- 17 February 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (2) , 255-259
Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol
For infantile hemangiomas (IH) requiring treatment, including those in high‐risk locations or in the setting of ulceration, oral propranolol is first‐line therapy. Here, we present three cases of infantile hemangioma with worsening ulceration following initiation or escalation of oral propranolol at standard doses.
- 17 February 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (2) , 255-259
Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol
For infantile hemangiomas (IH) requiring treatment, including those in high‐risk locations or in the setting of ulceration, oral propranolol is first‐line therapy. Here, we present three cases of infantile hemangioma with worsening ulceration following initiation or escalation of oral propranolol at standard doses.
- 10 January 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (2) , 316-319
Successful management of an arteriovenous malformation with trametinib in a patient with capillary‐malformation arteriovenous malformation syndrome and cardiac compromise
Capillary malformation‐arteriovenous malformation (CM‐AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16‐year‐old woman with CM‐AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen‐activated protein kinase (MEK) inhibitor.
- 10 January 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (2) , 316-319
Successful management of an arteriovenous malformation with trametinib in a patient with capillary‐malformation arteriovenous malformation syndrome and cardiac compromise
Capillary malformation‐arteriovenous malformation (CM‐AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16‐year‐old woman with CM‐AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen‐activated protein kinase (MEK) inhibitor.
- Open Access
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1222-1225
Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS‐CoV‐2 and influenza A
Reactive infectious mucocutaneous eruption (RIME) was proposed as new terminology to encompass postinfectious mucocutaneous eruptions. The term includes all postinfectious mucocutaneous eruptions such as the widely reported Mycoplasma pneumoniae‐induced rash and mucositis (MIRM). Very few reports in the literature regarding recurrent RIME are found. We present two adolescent cases of recurrent RIME that involve SARS‐CoV‐2 and influenza A where the latter is a newly reported infectious trigger; in both patients, the initial episode was likely triggered by Mycoplasma pneumoniae (MP) infection.
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1222-1225
Open AccessRecurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS‐CoV‐2 and influenza A
Reactive infectious mucocutaneous eruption (RIME) was proposed as new terminology to encompass postinfectious mucocutaneous eruptions. The term includes all postinfectious mucocutaneous eruptions such as the widely reported Mycoplasma pneumoniae‐induced rash and mucositis (MIRM). Very few reports in the literature regarding recurrent RIME are found. We present two adolescent cases of recurrent RIME that involve SARS‐CoV‐2 and influenza A where the latter is a newly reported infectious trigger; in both patients, the initial episode was likely triggered by Mycoplasma pneumoniae (MP) infection.